Last Updated : September 22, 2023
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Adlyxine | lixisenatide | Diabetes mellitus, Type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
Admelog | Insulin lispro | Cancelled | ||||
Adtralza | tralokinumab | atopic dermatitis | Do not reimburse | Complete | ||
Adtralza | tralokinumab | atopic dermatitis (AD) | Active | |||
Aduhelm | aducanumab | Alzheimer’s disease | Withdrawn | |||
Advicor | Niacin/lovastatin | Hypercholesterolemia and mixed dyslipidemia | List | Complete | ||
Aermony RespiClick | fluticasone propionate | Asthma | Reimburse with clinical criteria and/or conditions | Complete | ||
Afinitor | Everolimus | Neuroendocrine tumors (NET) of Gastrointestinal or Lung origin | Reimburse with clinical criteria and/or conditions | Complete | ||
Afinitor | Everolimus | Pancreatic Neuroendocrine Tumour | Reimburse with clinical criteria and/or conditions | Complete | ||
Afinitor | Everolimus | Advanced Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete |